Survival of patients with metastatic breast carcinoma: Importance of prognostic markers of the primary tumor

Cancer

Volumn 97, Issue 3, 2003, Pages 545-553

  Chang, Jenny ^a,b   Clark, Gary M ^a   Allred, D Craig ^a   Mohsin, Syed ^a   Chamness, Gary ^a   Elledge, Richard M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Bcl 2; Breast carcinoma; Progesterone receptor; Prognosis; S phase fraction

Indexed keywords

ESTROGEN RECEPTOR; ONCOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE S PHASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MULTIVARIATE ANALYSIS; ONCOGENE C ERB; OUTCOMES RESEARCH; PHENOTYPE; PLOIDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; STATISTICAL ANALYSIS; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037301972     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11083     Document Type: Article

References (25)

1. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:2197-2205.
2. Clark G, Sledge GWJ, Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol. 1987;5:55-61.
3. Howell A, Barnes DM, Harland RN, et al. Steroid-hormone receptors and survival after first relapse in breast cancer. Lancet. 1984;18377:588-591.
4. Insa A, Lluch A, Prosper F, Marugan I, Martinez-Agullo A, Garcia-Conde J. Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat. 1999;56:67-78.
5. Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med. 1989;320:627-633.
6. Elledge RM, Green S, Howes L, et al. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive meta-static breast cancer: a Southwest Oncology Group study. J Clin Oncol. 1997;15:1916-1922.
7. Krajewski SBC, Franssila K, Kranjewska M, et al. Reduced expression of proapototic gene Bax is associated with response rates to combination chemotherapy and shorter survival in metastatic breast cancer. Cancer Res. 1995;55:4471-4478.
8. Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert P, Van Marck E. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer. 1995;72:354-360.
9. Elledge RM, Allred DC. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat. 1998; 52:79-98.
10. Solomayer E-F, Diel IJ, Meyberg GC, Gollan C, Bastert G. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat. 2000;59:271-278.
11. Pater JL, Mores D, Loeb M. Survival after recurrence of breast cancer. Can Med Assoc J. 1981; 124:1591-1595.
12. Vogel CL, Schoenfelder J, Shemano I, Hayes DF, Gams RA. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol. 1995;13:1123-1128.
13. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990;8:103-112.
14. Andrulis IL, Bull SB, Blackstein ME, et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol. 1998;16:1340-1349.
15. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol. 1992;10:1049-1056.
16. Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumour suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992;84:845-855.
17. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993;85:200-206.
18. Niskanen E, Blomqvist C, Franssila K, Hietanen P, Wasenius VM. Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br J Cancer. 1997;76:917-922.
19. Horwitz KB, McGuire WL, Pearson OH, Segaloff A. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science. 1975;189:726-727.
20. Ravdin PM, Green S, Dorr TM, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol. 1992;10:1284-1291.
21. Silvestrini R, Veneroni S, Daidone MG, et al. The Bcl-2 protein: a prognostic indicator related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst. 1994;86:499-504.
22. Leek RD, Kaklamanis L, Pezzella F, et al. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer. 1994;69:135-139.
23. Gasparini BM, Doglioni C, Palma PL, et al. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res. 1995; 1:189-198.
24. O'Reilly SM, Camplejohn RS, Millis RR, Rubens RD, Richards MA. Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer. Eur J Cancer. 1990;26:1035-1038.
25. Hatschek T, Carstensen J, Fagerberg G, Stal O, Grontoft O, Nordenskjold B. Influence of S-phase on metastatic pattern and post-recurrence survival in a randomized mammography screening trial. Breast Cancer Res Treat. 1989;14: 321-327.